Form 8-K - Current report:
SEC Accession No. 0001628280-17-004500
Filing Date
2017-04-28
Accepted
2017-04-28 17:00:04
Documents
4
Period of Report
2017-04-28
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K - KRISTALOSE CO-PROMOTION AGREEMENT a8k-kristalosecoxpromotion.htm 8-K 24453
2 EXHIBIT 99.1 - PRESS RELEASE CO-PROMOTION pressrelease-coxpromotiona.htm EX-99.1 20299
3 cumberlanda04.gif GRAPHIC 10657
4 polu.jpg GRAPHIC 14452
  Complete submission text file 0001628280-17-004500.txt   80566
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 17796703
SIC: 2834 Pharmaceutical Preparations